Literature DB >> 12453876

Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient.

Wanda Piacibello1, Stefania Bruno, Fiorella Sanavio, Sara Droetto, Monica Gunetti, Laurie Ailles, Francesca Santoni de Sio, Andrea Viale, Loretta Gammaitoni, Angelo Lombardo, Luigi Naldini, Massimo Aglietta.   

Abstract

The ability of advanced-generation lentiviral vectors to transfer the green fluorescent protein (GFP) gene into human hematopoietic stem cells (HSCs) was studied in culture conditions that allowed expansion of transplantable human HSCs. Following 96 hours' exposure to flt3/flk2 ligand (FL), thrombopoietin (TPO), stem cell factor (SCF), and interleukin-6 (IL-6) and overnight incubation with vector particles, cord blood (CB) CD34(+) cells were further cultured for up to 4 weeks. CD34(+) cell expansion was similar for both transduced and control cells. Transduction efficiency of nonobese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cells (SRCs) was assessed by transplants into NOD/SCID mice. Mice that received transplants of transduced week 1 and week 4 expanded cells showed higher levels of human engraftment than mice receiving transplants of transduced nonexpanded cells (with transplants of 1 x 10(5) CD34(+) cells, the percentages of CD45(+) cells were 20.5 +/- 4.5 [week 1, expanded] and 27.2 +/- 8.2 [week 4, expanded] vs 11.7 +/- 2.5 [nonexpanded]; n = 5). The GFP(+)/CD45(+) cell fraction was similar in all cases (12.5% +/- 2.9% and 12.2% +/- 2.7% vs 12.7% +/- 2.1%). Engraftment was multilineage, with GFP(+)/lineage(+) cells. Clonality analysis performed on the bone marrow of mice receiving transduced and week 4 expanded cells suggested that more than one integrant likely contributed to the engraftment of GFP-expressing cells. Serial transplantations were performed with transduced week 4 expanded CB cells. Secondary engraftment levels were 10.7% +/- 4.3% (n = 12); 19.7% +/- 6.2% of human cells were GFP(+). In tertiary transplants the percentage of CD45(+) cells was lower (4.3% +/- 1.7%; n = 10); 14.8% +/- 5.9% of human cells were GFP(+), and human engraftment was multilineage. These results show that lentiviral vectors efficiently transduce HSCs, which can undergo expansion and maintain proliferation and self-renewal ability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453876     DOI: 10.1182/blood.V100.13.4391

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.

Authors:  Suzan Imren; Mary E Fabry; Karen A Westerman; Robert Pawliuk; Patrick Tang; Patricia M Rosten; Ronald L Nagel; Philippe Leboulch; Connie J Eaves; R Keith Humphries
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 2.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

3.  Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Authors:  Peter Ebeling; P Bach; U Sorg; A Schneider; T Trarbach; D Dilloo; H Hanenberg; S Niesert; S Seeber; T Moritz; M Flasshove
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-20       Impact factor: 4.553

4.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.

Authors:  Hal E Broxmeyer; Jonathan Hoggatt; Heather A O'Leary; Charlie Mantel; Brahmananda R Chitteti; Scott Cooper; Steven Messina-Graham; Giao Hangoc; Sherif Farag; Sara L Rohrabaugh; Xuan Ou; Jennifer Speth; Louis M Pelus; Edward F Srour; Timothy B Campbell
Journal:  Nat Med       Date:  2012-11-18       Impact factor: 53.440

Review 5.  Hematopoietic stem cell expansion and gene therapy.

Authors:  Korashon Lynn Watts; Jennifer Adair; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2011-11       Impact factor: 5.414

6.  Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34(+) NOD/SCID-repopulating cells.

Authors:  Ying Liu; Giao Hangoc; Timothy B Campbell; Michael Goodman; Wen Tao; Karen Pollok; Edward F Srour; Hal E Broxmeyer
Journal:  Exp Hematol       Date:  2008-08       Impact factor: 3.084

7.  Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates.

Authors:  Lajos Mátés; Marinee K L Chuah; Eyayu Belay; Boris Jerchow; Namitha Manoj; Abel Acosta-Sanchez; Dawid P Grzela; Andrea Schmitt; Katja Becker; Janka Matrai; Ling Ma; Ermira Samara-Kuko; Conny Gysemans; Diana Pryputniewicz; Csaba Miskey; Bradley Fletcher; Thierry VandenDriessche; Zoltán Ivics; Zsuzsanna Izsvák
Journal:  Nat Genet       Date:  2009-05-03       Impact factor: 38.330

Review 8.  Cord blood transplant: strategy of alternative donor search.

Authors:  Eliane Gluckman; Vanderson Rocha
Journal:  Springer Semin Immunopathol       Date:  2004-07-29

9.  Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction.

Authors:  Francesca Romana Santoni de Sio; Paolo Cascio; Anna Zingale; Mauro Gasparini; Luigi Naldini
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

10.  Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells.

Authors:  Michelle Millington; Allison Arndt; Maureen Boyd; Tanya Applegate; Sylvie Shen
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.